Summary
- ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months.
- The market continues to reward its hypothesis in treating primary humoral immunodeficiency.
- Shares have extended the rally in 2023 and further upside would see the ADMA share price push above its previous highs.
- The company's FY22 results, to be released in March, are a key inflection point to see what's in store for investors this year.
- Net-net, we rate ADMA a buy.
For further details see:
ADMA Biologics: FY22 Numbers Key Inflection Point